Bright Minds Biosciences (DRUG) Expected to Post Quarterly Earnings on Thursday

Bright Minds Biosciences (NASDAQ:DRUG) is expected to announce its Q3 2026 results before the market opens on Thursday, August 13th. Analysts expect Bright Minds Biosciences to post earnings of ($1.2831) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Thursday, August 20, 2026 at 4:00 PM ET.

Bright Minds Biosciences (NASDAQ:DRUG) last posted its earnings results on Wednesday, May 20th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.06. On average, analysts expect Bright Minds Biosciences to post $-5 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Bright Minds Biosciences Trading Up 1.8%

Shares of DRUG stock opened at $80.79 on Tuesday. The business’s 50-day moving average price is $70.32 and its 200-day moving average price is $77.35. Bright Minds Biosciences has a 12 month low of $37.47 and a 12 month high of $123.75. The firm has a market capitalization of $786.09 million, a price-to-earnings ratio of -33.11 and a beta of -5.27.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DRUG. HC Wainwright reiterated a “buy” rating and set a $145.00 target price on shares of Bright Minds Biosciences in a research report on Monday, June 1st. Zacks Research upgraded shares of Bright Minds Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Wall Street Zen raised shares of Bright Minds Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 4th. Piper Sandler reiterated an “overweight” rating and set a $220.00 price target (up from $190.00) on shares of Bright Minds Biosciences in a report on Wednesday, May 20th. Finally, Jefferies Financial Group started coverage on shares of Bright Minds Biosciences in a research note on Monday, April 13th. They issued a “buy” rating and a $145.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $143.83.

Hedge Funds Weigh In On Bright Minds Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in Bright Minds Biosciences by 240.0% during the 4th quarter. Royal Bank of Canada now owns 527 shares of the company’s stock worth $40,000 after acquiring an additional 372 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Bright Minds Biosciences by 624.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock valued at $57,000 after purchasing an additional 1,873 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Bright Minds Biosciences during the third quarter worth approximately $58,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Bright Minds Biosciences in the second quarter worth approximately $66,000. Finally, New York State Common Retirement Fund acquired a new position in Bright Minds Biosciences in the second quarter valued at approximately $107,000. Institutional investors and hedge funds own 40.52% of the company’s stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.